Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 190

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 190
---
 into a loan agreement with our Chief
Executive Officer, or the December 2024 Loan Agreement, according to which accrued payroll salary owed to him in the aggregate amount
of $117,000 plus VAT was converted into a loan. The loan amount bears interest at an 8% annual rate, and is due upon the earlier of the
consummation of this offering or March 31, 2025. In addition, upon maturity, the Company will pay to our Chief Executive Officer an aggregate
risk premium equal to 30% of the loan amount (or approximately $35,000). If a registration statement for an initial public offering is
made effective no later than March 31, 2025, then the maturity date will be extended to June 30, 2025. In addition, pursuant to the December
2024 Loan Agreement, upon the consummation of this offering the Company will issue warrants, or the CEO Loan Warrants, exercisable for
a period of three years from the date of the issuance, to purchase such number of Ordinary Shares equal to two times the respective loan
amount divided by 75% of the lowest price per Ordinary Share during the first five trading days following the consummation of this offering,
at an exercise price equal to 75% of the lowest price per Ordinary Share during the first five trading days following the consummation
of this offering. The outstanding debt will become immediately due and payable upon an event of default (as defined in the December 2024
Loan Agreement), which shall be deemed to have occurred upon certain circumstances as detailed in the December 2024 Loan Agreement

<div align='center'>116</div>

Agreements and Arrangements With, and Compensation of, Directors and Executive Officers

Certain of our executive
officers have employment agreements with us. These agreements will terminate at the closing of this offering and will be replaced by
new employment agreements, which will contain customary provisions and representations, including confidentiality, non-competition, non-solicitation
and inventions assignment undertakings by the executive officers. None of our employment or service provider agreements contain any terms
providing for severance benefits. Under current applicable Israeli employment laws, we may not be able to enforce (either in whole or
in part) covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some of
our former employees. See “Management—Compensation of Executive Officers and Directors”. In addition, certain of